Immunome (IMNM) Director Isaac Barchas Sells Shares

What Happened
Isaac Barchas, a director of Immunome Inc. (IMNM), sold a total of 83,464 shares in three open‑market dispositions between Aug 10–12, 2026, generating about $2,198,910 in proceeds. The individual transactions were: 10,125 shares at a weighted avg. $26.07 on Aug 10 ($263,959); 62,291 shares at a weighted avg. $26.23 on Aug 11 ($1,633,893); and 11,048 shares at $27.25 on Aug 12 (~$301,058). These were sales (routine dispositions), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-08-10: 10,125 shares sold, weighted avg $26.07 (range $26.005–$26.14). (Footnote F2)
  • 2026-08-11: 62,291 shares sold, weighted avg $26.23 (range $26.00–$26.48). (Footnote F4)
  • 2026-08-12: 11,048 shares sold at $27.25.
• Total shares sold: 83,464; total proceeds: approx. $2,198,910.
• Ownership after transaction: Not specified in the supplied filing.
• Notable footnotes:
  • Sales were made automatically under a Rule 10b5‑1 trading plan (AMBHMC II LLC / reporting‑person plan adopted March 31, 2026). (F1, F5)
  • ABHMC II LLC holds the shares; Barchas is a managing member and has voting/investment power but disclaims beneficial ownership except for any pecuniary interest. (F3)
  • Detailed per‑price breakdowns are available on request (per F2/F4).
• Filing: Report filed Aug 12, 2026 covering trades Aug 10–12; no late‑filing indication provided.

Context
These sales were executed under prearranged Rule 10b5‑1 plans and involved shares held by an entity (ABHMC). Rule 10b5‑1 sales are typically automated per plan terms and do not necessarily indicate a change in the insider’s near‑term view of the company.